Equities research analysts predict that Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) will announce earnings per share (EPS) of ($0.61) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Iovance Biotherapeutics’ earnings. The lowest EPS estimate is ($0.65) and the highest is ($0.55). Iovance Biotherapeutics posted earnings per share of ($0.53) during the same quarter last year, which suggests a negative year-over-year growth rate of 15.1%. The firm is expected to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Iovance Biotherapeutics will report full-year earnings of ($2.46) per share for the current fiscal year, with EPS estimates ranging from ($2.80) to ($2.19). For the next year, analysts anticipate that the firm will report earnings of ($2.19) per share, with EPS estimates ranging from ($2.81) to ($1.41). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Iovance Biotherapeutics.
Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.06. The firm had revenue of $12.00 million during the quarter. Iovance Biotherapeutics’s revenue was up .0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.51) EPS.
NASDAQ:IOVA opened at $15.43 on Wednesday. The stock’s 50 day moving average price is $15.85 and its two-hundred day moving average price is $16.85. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of -6.74 and a beta of 0.86. Iovance Biotherapeutics has a 12-month low of $11.91 and a 12-month high of $28.00.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Herold Advisors Inc. bought a new stake in shares of Iovance Biotherapeutics during the 1st quarter valued at $33,000. Spire Wealth Management acquired a new position in Iovance Biotherapeutics in the first quarter valued at about $47,000. Lazard Asset Management LLC raised its stake in Iovance Biotherapeutics by 38.5% in the first quarter. Lazard Asset Management LLC now owns 3,357 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 934 shares in the last quarter. Neo Ivy Capital Management acquired a new position in Iovance Biotherapeutics in the fourth quarter valued at about $55,000. Finally, Retirement Group LLC raised its stake in Iovance Biotherapeutics by 85.1% in the first quarter. Retirement Group LLC now owns 4,350 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 2,000 shares in the last quarter. 99.07% of the stock is owned by hedge funds and other institutional investors.
About Iovance Biotherapeutics (Get Rating)
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.
- Get a free copy of the StockNews.com research report on Iovance Biotherapeutics (IOVA)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.